Newton, Mass., February 10, 2006.
NeuroHealing Pharmaceuticals Inc., a private company developing products for individuals with chronic brain injuries, announces that preliminary results from its ongoing clinical studies of NH001 for coma patients will be presented by Dr. Esteban Fridman at the 4th World Neurorehabilitation Congress to take place in Hong Kong on February 12-16, 2006.
“The preliminary results observed in both clinical sites in Argentina and Israel are extremely encouraging and suggest that we are in the right path to find a drug therapy for patients in a post-traumatic coma“, said Dr. Esteban Fridman, Principal Investigator at the FLENI Hospital in Buenos Aires, Argentina. Dr. Fridman mentioned “these preliminary results bring hope to a patient population which is still waiting for medical breakthroughs observed in other areas of medicine.”
The findings to be presented will include the response to NH001 treatment of the first four patients recruited. Dr. Ben-Zion Krimchansky, co-Principal Investigator and responsible for patient treatment at another clinical site at the Lowenstein Rehabilitation Hospital, Israel said, “the fast rate of recovery in the last patient we treated with NH001 was unforeseen and beyond our expectations. We look forward to continue recruiting patients for this study.”
About Coma, Vegetative State and Minimally Conscious State
Advances in the acute management of traumatic brain injury have led to increased survival of severely brain-injured patients. Each year 50-75,000 patients in the US survive severe brain injury but remain in an altered consciousness state. Patients that remain in prolonged coma usually evolve to a persistent vegetative state or a minimally conscious state, characterized by the regaining of arousal but with little capacity for awareness, attention or the ability for independent living.
In the acute stage the main medical efforts are focused on stabilizing the vital signs, internal homeostasis and intracranial pressure. Presently, there is no approved pharmaceutical treatment for post-traumatic patients who remain in a vegetative state or minimally conscious state. After the patient reaches stability, current therapy is limited to sensory stimulation.
NeuroHealing’s proprietary therapy NH001 is a potent dopaminergic agonist with well-established human safety data, an appropriate phamacokinetic profile and a convenient route of administration. It is a direct acting dopamine agonist at both D1 and D2 receptors, and has been reported to stimulate post-synaptic dopamine receptors independent of pre-synaptic dopamine synthesis or stores. It rapidly crosses the blood brain barrier and reaches a concentration in the brain eight times higher than that in plasma.
Because dopaminergic function appears to be of importance in executive central nervous system function, such as arousal and memory, NH001 may stimulate recovery from a coma.
NeuroHealing develops and commercializes novel therapeutics based on new formulation strategies to treat the needs of post-acute neuro-rehabilitation patients, including disorders such as traumatic brain injury, stroke, Parkinson’s disease and other motor neuron diseases.